Previous close | 0.2000 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 0.1500 |
Strike | 7.00 |
Expiry date | 2024-12-20 |
Day's range | 0.2000 - 0.2000 |
Contract range | N/A |
Volume | |
Open interest | 11 |
Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the FDA acknowledged the receipt of the Company's Prior Approval Supplement ("PAS") application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN. The FDA has assigned a PDUFA goal date of September 23, 2024.
Key Insights Significantly high institutional ownership implies Heron Therapeutics' stock price is sensitive to their...